Skip to main
PRME
PRME logo

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine Inc. is advancing its Prime Editing technology, which has demonstrated the capability to efficiently correct genetic defects in patient-derived cells, with notable potential applications in treating diseases with significant unmet medical needs. The company recently enhanced its financial position by closing an offering of 43.7 million shares at $3.3 per share, generating net proceeds of $138.2 million, strengthening its cash reserves to approximately $158.3 million by the end of the first quarter of 2025. Additionally, promising results from studies indicate improvements in key health metrics, such as a substantial reduction in inflammatory markers for patients, supporting the viability of its gene editing therapies and enhancing positive investor sentiment.

Bears say

Prime Medicine Inc. faces significant risks regarding regulatory approval for its gene editing products, which could lead to downward revisions of risk-adjusted projections even if clinical endpoint targets are met. Should the regulatory pathway be more complex or lengthy than expected, this could further exacerbate potential negative impacts on financial outcomes. As a result, the uncertainty surrounding regulatory approvals raises concerns about the overall viability and future profitability of Prime Medicine's stock.

PRME has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 6 analysts, PRME has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.